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Vulnerable populations (including homeless persons, high-risk drug and alcohol users, prisoners, and 
other marginalized populations) contribute a disproportionate burden of tuberculosis (TB) cases in 
low-incidence settings. Drivers for this disease burden include increased risk of both TB transmission 
in congregate settings, and progression from infection to active disease.  Late diagnosis and poor 
treatment completion further propagate the epidemic and fuel the acquisition of drug-resistance. 
These groups are therefore a major priority for TB control programmes in low-incidence settings. 
Targeted strategies include active case finding initiatives and interventions to improve treatment 
completion, and should be tailored to local populations. Active case finding most commonly deploys 
mobile x-ray unit screening, which allows sensitive, high throughput screening with immediate 
availability of results. Such initiatives have been found to be effective and cost-effective, and 
associated with reductions in proxy measures of transmission among hard-to-reach groups. The 
addition of point-of-care molecular diagnostics and automated x-ray readers may further streamline 
the screening pathway. There is little existing evidence to support interventions to improve adherence 
among these risk groups. Such approaches include enhanced case-management and directly-observed 
therapy, while video-observed therapy (currently under evaluation) appears to be a promising tool for 
the future. Integrating outreach services to include both case-detection and case-management 
interventions that share a resource infrastructure may allow cost-effectiveness to be maximised. 
Integrating screening and treatment for other diseases prevalent among targeted risk groups into TB 
outreach interventions may improve cost-effectiveness further. This article reviews the existing 
literature, and highlights priorities for further research.   





The World Health Organization (WHO) End TB strategy, aiming to reduce tuberculosis (TB) 
incidence and TB mortality by 90% and 95% respectively by 2035, poses major challenges to TB 
control programmes in low TB incidence settings (defined as countries with an annual incidence of 
10 / 100,000)1. The goal in these settings is to achieve pre-elimination (defined as an annual 
incidence of <1 / 100,000) and to move towards elimination by 20352. In order to achieve this, the 
setting-specific challenges in TB control in these low-incidence countries must be addressed. This 
requires special attention to specific populations at highest risk of TB disease, among whom much of 
the disease burden is now concentrated2–4.  
 
Vulnerable populations (including homeless persons, high-risk drug users, prisoners, asylum seekers, 
and other marginalized populations) contribute a disproportionate number of TB cases in low-
incidence settings1–3. Previous studies have attempted to quantify these disease burdens. Studies of 
homeless people have shown that the prevalence of active TB is heterogeneous, ranging from 200-
7,700/100,000, with increased prevalence found in studies using chest radiography-based diagnosis, 
and in settings with higher general population TB prevalence5. Using systematic review and meta-
analysis, Dolan et al. estimated that approximately 2,800/100,000 of incarcerated individuals globally 
have active TB6. Among high-risk drug users in London, UK, the prevalence of TB was estimated at 
354/100,000, with a high proportion of cases being sputum smear-positive7. Alcohol-dependence is 
also associated with increased TB risk, estimated as a pooled relative risk of 2.94 in a systematic 
review and meta-analysis8,9.  
 
Multiple drivers contribute to the elevated incidence of TB among these groups. Firstly, individuals in 
these groups are often at higher risk of TB exposure due to socio-environmental conditions that 
predispose to increased TB transmission, including in congregate settings such as homeless shelters 
and prisons10–12. Secondly, they are often at greater risk of progression from infection to TB disease. 
This may be due to several, synergistic factors, including poor nutrition13, co-infection with HIV14, 
alcohol misuse8 or high-risk drug use15,16. These factors are propagated by TB cases within these 
groups often being diagnosed late (due to a lack of access to healthcare and late recognition of 
symptoms), and frequently receiving suboptimal therapy (due to the challenges of linkage and 
retention in care, and ensuring sustained adherence to treatment)15. This, in turn, increases the 
potential duration of their infective period, thereby increasing the risks of onward TB transmission, 
and the acquisition of drug-resistance. Further, when TB cases are eventually diagnosed, conventional 
contact investigations are often inadequate due to the difficulty of identifying contacts reliably17. 
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Recent global and European guidance highlights a clear need to strengthen TB control efforts among 
vulnerable groups in low-incidence settings1,3. Approaches addressing this may include active case 
finding initiatives, in order to promote early case-detection of TB disease, along with interventions 
that improve linkage and retention in TB care, to increase treatment completion. This narrative review 
will discuss active case finding and adherence interventions when targeting homeless persons, high-
risk drug users, prisoners, and other marginalised populations in low-incidence settings. Other 
important risk-groups include recent migrants and people living with HIV; these are beyond the scope 
of this review, as they are included in other articles in this series14,18. A literature search was 
conducted to support this review (Box 1). Definitions of key terms used in this review, including 
active case finding and adherence, are included in Box 2.  
 
 
Active case finding in risk groups in the TB pre-elimination era 
 
Screening tools and algorithms 
 
Active case finding involves the systematic identification of individuals with suspected active TB, in 
a pre-determined target group19. This requires the implementation of a pre-defined screening 
algorithm and may utilise tools including symptom questionnaires, chest radiographs (either mobile or 
off-site), or sputum diagnostics. Desirable qualities of a screening algorithm include high sensitivity, 
low cost, high throughput and rapid turnaround time. Table 1 summarises the sensitivity of available 
screening tools. 
 
Symptom screening is generally thought to be of little value in risk groups in low-incidence settings 
due to limitations of poor sensitivity and specificity (particularly among populations with high 
prevalence of smoking, alcohol and drug use)19,20. Data evaluating the use of symptom screening as 
the sole initial screening tool are therefore scarce, though it may be used in combination with other 
methods.  
 
Chest radiography, previously deployed for mass radiography screening for TB21, has re-emerged as a 
valuable initial screening tool among risk groups in recent years due to a number of strengths. These 
include:- the development of mobile digital radiography; relatively low cost; high throughput; high 
diagnostic accuracy; and immediate availability of results22–25. Chest radiography, regardless of 
symptoms, has therefore been the initial screening test of choice in the majority of recent studies 
evaluating active case finding interventions among risk groups in low-incidence settings. It should be 
noted, however, that sensitivity is reduced in populations with a high prevalence of advanced HIV 
infection - which may be relevant to some high-risk groups (e.g. injecting drug users) targeted by 
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interventions26. An example screening algorithm using a mobile x-ray unit (MXU) is demonstrated in 
Figure 1.  
 
Sputum diagnostic tools for TB include smear microscopy, culture and molecular tests. Smear 
microscopy, while cheap and relatively fast to perform, is limited by poor sensitivity so is of little 
value as a screening tool19. Mycobacterial culture remains the gold-standard for the microbiological 
diagnosis of TB. It has generally been thought to have a limited role in active case finding among 
hard-to-reach groups in low-incidence settings due to the limitations of being dependent upon 
individuals’ ability to produce good quality sputum samples, and slow turnaround time (up to 6 
weeks) – which raises the challenge of locating positive cases after their initial screening23. However, 
a recent study in Copenhagen, Denmark, has shown that it may be of value in some settings27. Current 
molecular diagnostic tests, such as the Xpert MTB/RIF assay (Cepheid, Sunnyvale, USA), are 
relatively sensitive, very specific and allow fast turnaround time (<2 hours)28. They also have the 
potential for implementation at the point-of-care, though high cost and limited throughput mean that 
they are not currently viable as an initial screening tool, but may be reserved as diagnostic tools for 
individuals identified as high-risk of TB from the initial stage of the screening algorithm. Novel point-
of-care molecular diagnostics are in the pipeline, and offer the hope of implementation as first-line 
screening tests in the future29.  
 
Another approach to active case finding among risk groups is the combination of a symptom screen 
and tuberculin skin-test (TST) as the initial screening tools, with chest radiography performed if either 
is positive30–33. While both methods have low sensitivity for active TB when used in isolation, this 
approach relies on a high negative predictive value when both are negative. However, drawbacks 
include low specificity, and the requirement for at least two visits to read results. Interferon-gamma 
release assays (IGRA) also continue to be evaluated as tests for active TB34, but are also impaired by 
limited sensitivity, high cost and the requirement of a specialist laboratory35. Both TST and IGRA are 
therefore more commonly applied when the primary goal is screening for LTBI rather than TB 
disease.  
 
Table 2 summarises published studies evaluating active case finding interventions among high-risk 
groups in low-incidence settings.  
 
Mobile x-ray unit screening 
 
Multiple studies have evaluated MXU screening approaches. The Find & Treat service in London, 
UK, involves a MXU screening intervention, targeting a mixed hard-to-reach population that includes 
homeless persons, prisoners, high-risk drug users and asylum seekers36–38. The service was initiated 
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after previous UK studies demonstrated the potential utility of active case finding using MXUs among 
these risk groups in UK cities39–43. The service has been evaluated in a number of studies. Story et al. 
linked individuals screened by the service to the national electronic surveillance system and 
demonstrated that the MXU diagnosed active TB with a sensitivity of 81.8% and specificity of 
99.2%36. This study also found that cases identified by the MXU were less likely to be smear-positive 
than matched, passively-diagnosed controls, thereby implying that the intervention may be effective 
in diagnosing active TB cases earlier, and suggesting a potential impact of earlier diagnosis on 
reducing risk of onward transmission36. Jit et al. conducted a cost-effectiveness evaluation of the 
intervention. Case-detection by the service was found to be cost-effective (£18,000 - £26,000 / QALY 
gained)38. Further, 35.4% of cases diagnosed by the service were asymptomatic, while 22.9% had 
been symptomatic for >131 days, suggesting that these individuals were unlikely to be diagnosed 
without the intervention38.  
 
Mobile x-ray unit screening targeting homeless people across 28 shelters in Paris over a 14-year 
period  found 179 TB cases (from an estimated 22,000 screened), and was associated with a reduction 
in the proportion of cases that were clustered over time, using restriction fragment length 
polymorphisms (RFLP), as a proxy measure of recent transmission44. De Vries et al. evaluated a 
similar intervention, targeting homeless people and high-risk drug users, in Rotterdam, The 
Netherlands. Over a 4-year period, 28 active TB cases were diagnosed by the intervention (prevalence 
327/100,000); the authors also reported a reduction in RFLP-clustering over a time, suggesting a 
decline in recent transmission45. Implementation of the intervention as part of a wider comprehensive 
social rehabilitation programme for homeless people and drug users was associated with a marked 
reduction in TB incidence among these risk groups in Rotterdam over time. This resulted in a 
subsequent reduction in efficiency and yield of the intervention, which was therefore deemed no 
longer necessary and withdrawn at the end of 201446.  
 
In a systematic review and meta-analysis of 16 studies from Western Europe, Japan, USA and 
Australia, the pooled prevalence of active TB from chest radiography screening of homeless people 
was estimated as 931/100,000 (range 434 – 3,015)22.  
 
Other active case finding approaches 
 
Jensen et al. implemented spot sputum screening (using microscopy and culture) among a mixed 
hard-to-reach population in Copenhagen in Denmark27. They demonstrated an initial TB prevalence of 
2,233/100,000. Only 7/36 (19.4%) of cases were sputum smear-positive, and only 83.3% had chest 
radiographic changes suggestive of TB, suggesting that the remaining 17% may not have been 
diagnosed by an MXU intervention. While the median time to treatment was 32 days, it is 
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encouraging that all cases diagnosed started TB therapy, of whom 83% completed. This study 
demonstrates that spot sputum screening may be feasible, particularly in settings where MXUs are not 
available, though further data are clearly required as locating individuals with positive culture results 
days or weeks after screening may yet prove to be challenging in practice.  
 
Active referral to TB services for screening is another intervention that has been evaluated in 
European studies among drug users, homeless persons and migrants, finding a TB prevalence of 300-
1,217/100,000 among those screened47,48. Other studies from the USA using a symptom screen and 
TST as the initial screening test, with further evaluation including chest radiograph performed only if 
positive, have demonstrated a TB prevalence ranging from 0-1,217/100,000 among homeless 
people30–33. Two of these studies reported a reduction in TB incidence in US cities over the duration 
of the intervention, though other biomedical and socioeconomic factors may have contributed to these 
trends32,33.  Screening of inmates on entry to prisons has been evaluated in Spanish and USA studies. 
Algorithms used on entry in these studies have generally included an initial symptom screen and TST, 
followed by chest radiograph if either is positive, and have shown a prevalence of active TB of 68 – 
2,706/100,00049–55. However, performing a chest radiograph (rather than an initial symptom 
questionnaire and TST) as the initial screening test on prison entry has been associated with a 
reduction of exposure time to infectious TB cases (by expediting isolation)53,54, and a reduction in cost 
per case diagnosed56.  
 
Coverage & uptake of screening 
 
Ensuring adequate screening coverage and uptake must also be a priority for any active case finding 
intervention. Few studies have attempted to report coverage of screening programmes, which remains 
challenging to quantify in hard-to-reach groups due to the frequently mobile nature of these 
populations48,57. Acceptance and uptake of screening are also rarely reported, with uptake ranging 
from 14-87% in the absence of specific incentives40,41,43,58–61. Uptake is likely to be better with mobile 
(rather than off-site) screening programmes, though evidence for specific strategies to improve uptake 
is currently limited.  
 
Aldridge et al. conducted a cluster randomised-controlled trial to examine whether volunteer peer 
educators (with direct experience of TB and/or homelessness) improved uptake of MXU screening at 
hostels in London. No difference in uptake was observed (40% in the intervention group; 45% in the 
control group), though the study was limited by the intervention having previously been in place at 
‘standard care’ sites prior to the study being commenced, and therefore may have resulted in residual 
confounding and a reduction in the difference seen between the intervention and control arms59. Other 
studies from the USA have shown an increase in attendance to off-site chest radiograph referral with a 
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monetary incentive60 and at an initial follow-up appointment following a positive TST with either a 
monetary incentive, or a peer health advisor, when compared to standard care61.  
 
Yield of screening 
 
The weighted mean estimated number needed to screen has been estimated as 133 (range 22–1778), 
1180 (4–2945) and 158 (108–252) when targeting homeless persons, prisoners and drug users 
respectively in low-incidence settings19. However, these estimates are heterogeneous, reflecting 
differences in TB incidence between different risk groups, and between different settings. Active case 
finding interventions therefore require a targeted, setting-specific approach. This should be based on 
local epidemiological data that can identify those populations with sufficient disease burden to justify 
the provision of resources to enable focused interventions. Policymakers may use surveillance data, or 
even targeted prevalence surveys, to identify high-risk populations on a local level, and determine the 
potential yield and thus cost-effectiveness of proposed active case finding interventions.  
 
Future directions and research priorities for active case finding interventions 
 
Following a ‘positive’ initial screening test (e.g. a mobile chest radiograph in most recent studies), the 
most widely utilised screening algorithm involves referral to a TB service for further investigation as 
the next step [Figure 1]. Sputum may be sent for microbiological testing in parallel to this referral. A 
problem with this approach is the risk that they may not attend the TB service for further assessment, 
This initial loss-to-follow-up (which occurs prior to TB diagnosis) has been estimated as being as 
high as 31% in London37 and 50% in Sydney, Australia62. Implementation of ‘point-of-care’ 
molecular technology to enable a microbiological diagnosis on the day of initial screening following a 
suggestive chest radiograph is therefore attractive. Xpert MTB/RIF offers the potential to provide this 
in approximately two hours, using an automated platform28. This assay also allows the prompt 
identification of possible multidrug-resistance, through the detection of rifampicin-resistance 
conferring mutations. However, there are currently no studies published that evaluate the 
implementation of molecular diagnostics in a mobile outreach setting in a low-incidence country; data 
addressing this, including newer generations of the Xpert MTB/RIF assay or similar rapid molecular 
diagnostics, are therefore needed.  
 
Technology may also be applied to MXU screening algorithms through the implementation of 
automated x-ray readers (e.g. CAD4TB), which may reduce reliance on trained human readers while 
addressing issues with inter-reader reprodubility63 [Figure 1]. However, data validating the software 
for use in low-incidence settings and in a mobile screening unit are required prior to widespread roll-
out of the technology.  




As discussed above, the variable prevalence of TB among high-risk groups in low-incidence settings 
means that active case finding interventions require a tailored approach based on local 
epidemiological data, followed by monitoring and evaluation of cost-effectiveness and impact at a 
local level. The roll-out of universal whole genome sequencing (WGS) in some low-incidence 
settings may allow this to be done with greater resolution in future. When used in combination with 
conventional epidemiological methods, WGS may enable surveillance systems to identify sites and 
individuals that carry a high-risk of onward transmission earlier and more precisely than 
epidemiological methods alone have allowed, particularly in the context of outbreaks64–66. Prospective 
studies that evaluate the potential impact of real-time genomic data on local TB control policies are 
awaited.  
 
Qualitative studies have suggested that further increases in TB awareness, reduction in stigmatisation 
and improvements in perceived access to healthcare are all required to improve usage of TB services 
by risk groups67; further research is clearly needed to inform and evaluate strategies to address these 
needs. Engaging key partners, such as staff in prisons and shelters, is also integral to maximise uptake 
of screening programme targeting these groups.  
 
In addition to identifying active TB cases, consideration of testing and treating for LTBI among high-
risk groups is recommended (after exclusion of TB disease) in international and some national 
guidance in low-incidence settings68,69. Studies evaluating the yield of LTBI screening when 
implemented among risk groups in parallel to active TB case finding, along with acceptance and 
completion of LTBI treatment, and impact on incident TB risk are needed. Furthermore, risk groups 
for TB overlap with those for other diseases - including HIV, hepatitis B and hepatitis C70. Combining 
active case finding and linkage to care for these services for individuals in hard-to-reach groups may 
therefore be cost-effective by capitalising upon a shared resource infrastructure, though data to 
support this are currently lacking.  
 
 
Treatment adherence in risk groups in the TB pre-elimination era 
 
There have been few studies evaluating the role of interventions in improving adherence and active 
TB treatment completion among individuals from risk groups [Table 3]. Of these, 8 studies have 
evaluated enhanced case management interventions (including directly observed therapy (DOT), since 
this is not offered universally in low TB-incidence settings), while one has studied financial 
incentives.  
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Enhanced case management 
 
Three studies have evaluated interventions that involved an integrated approach of both active case 
finding and enhanced case management38,48. Jit et al. assessed the case management component of the 
London Find & Treat service, which supports treatment completion by maintaining contact with 
patients during treatment, accompanying them to clinic appointments, arranging visits in community, 
and involving peers38. The case management service supports hard-to-reach individuals diagnosed by 
the service, and referred from other local TB services. The evaluation by Jit et al. found that the case 
management component of the service was highly cost-effective (cost £4,100 - £6,800 per QALY 
gained). Treatment completion was 61.2% in the intervention cohort, compared to 51.7% with 
standard care after one year38.  
 
De Vries and colleagues provided a range of enhanced case management approaches in combination 
with their active case finding programme in Rotterdam45. This included DOT, priority shelter 
accommodation, voluntary admission to TB hospitals, assistance applying for temporary residence 
permits, and detention as a last resort for non-compliant, infectious cases (14 patients). Incentives 
such as public transport tickets were also provided. They achieved treatment completion of 89.2%. In 
Frankfurt, Germany, Goetsch et al. provided education and enhanced case management (delivered by 
community health workers) for drug users and homeless people diagnosed with active TB following 
active referral to TB services for screening, and achieved treatment completion in 76%48.  
 
Two studies have described enhanced cases management approaches including the provision of 
accommodation for homeless persons, achieving treatment completion of 80-90%71,72, along with a 
reduction in the mean period of hospitalisation after introduction of the intervention and a reduction in 
TB incidence among homeless persons in their locality over the study period71.  
 
Three studies have evaluated the effectiveness of DOT in improving treatment completion in a mixed 
hard-to-reach population. These studies demonstrated improved treatment completion with DOT 
compared to self-administered treatment73,74, particularly when provided in a community setting73 and 




Data on the use of financial incentives to improve adherence to therapy for TB in risk groups are 
lacking. In one study, Bock et al. studied the impact of financial incentives on treatment completion 
among a mixed hard-to-reach population in Georgia, USA, and found that DOT attendance improved 
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following the introduction of a grocery voucher incentive for each DOT attendance, when compared 
to attendance prior to the intervention76.  
 
Future directions and research priorities for treatment adherence interventions 
 
Video-observed therapy (VOT) is an exciting recent development, involving patients filming 
themselves taking medications on a computer or mobile device, before securely transmitting these 
images to a remote observer77. This technology may allow enhanced case management and DOT to 
offer a more patient-centred approach, bridging the gap between TB patients and their healthcare 
providers, and reducing the need for resource-intensive face-to-face encounters. Early studies have 
demonstrated that VOT is both feasible and acceptable to patients receiving TB treatment in the USA 
and Mexico78, and in Belarus79. A randomised-controlled trial comparing adherence to TB therapy 
when treatment is delivered by VOT vs. standard DOT among hard-to-reach patients in London has 
recently been completed with extremely promising initial results, though full published results are 
awaited80. 
 
While electronic reminder systems (e.g. short message service (SMS)) may also be of some benefit in 
improving adherence to appointments and treatment for TB services, the impact of such interventions 





Vulnerable groups - including homeless persons, prisoners, high-risk drug users and other 
marginalised groups – are a major priority for TB control programmes in low-incidence countries due 
to their disproportionate disease burden, ongoing high risk of transmission, and poor treatment 
outcomes. Interventions targeting these groups should aim to increase timely case-detection, and 
improve linkage-to-care and completion of therapy.  
 
Interventions must be tailored to address local priorities, based on knowledge of regional 
epidemiology and risk groups, and must be monitored and evaluated at a local level. Mobile x-ray 
units appear to be effective and cost-effective38 in achieving timely case-detection, and have been 
associated with reductions in proxy measures of transmission44,45. Implementation of new technology 
– including molecular diagnostics at the point-of-care (to expedite microbiological TB diagnosis), and 
universal whole genome sequencing (to supplement epidemiological data and identify transmission 
foci promptly) - may aid existing interventions to improve effectiveness in the future.  
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Interventions to improve treatment completion among these risk groups must also be tailored to 
individuals and may include enhanced case management (by both healthcare workers and peers), the 
provision of supervised accommodation for homeless persons, and supervised treatment (particularly 
when delivered in community and by peers). Incentives may also have a role, though evidence for this 
among risk groups are lacking. VOT is an extremely promising technology and is currently under 
evaluation as a tool to improve adherence in hard-to-reach groups. Integrating both active case finding 
and strategies to improve adherence into outreach interventions is likely to be cost-effective, by 
capitalising on shared resource infrastructure, while integrating testing and treatment for other 
diseases with overlapping risk profiles (e.g. HIV, hepatitis B and hepatitis C) into TB outreach 
services may improve overall cost-effectiveness further. 
 
However, high quality data evaluating the impact of active case finding initiatives and (in particular) 
interventions to improve treatment adherence among risk groups in low-incidence settings are 
generally lacking. More high-quality studies are required that examine the impact of such 
interventions on timely case-detection, treatment outcomes, risk of onward transmission, and 
maximising uptake of the interventions themselves. If the End TB strategy goals of achieving pre-
elimination and moving towards elimination in low-incidence settings by 2035 are to be reached, a 
concerted and prolonged effort will be required to reach these vulnerable groups, engage and retain 
them in care to the point of treatment completion. If we are serious about elimination, these efforts 
must be maintained even in light of falling cost-effectiveness, as TB incidence (and thus screening 
yield) declines. Finally, while this review has focused on biomedical interventions that aim to reduce 
the burden of TB disease among risk groups, we should not forget the imperative need to address the 
issue at its true core. We must continue to strive to improve access to healthcare among risk groups, 
while also reducing the size of risk group populations themselves, by implementing policies that seek 
to reduce health inequity and social exclusion directly. 
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Box 1: Search Strategy 
 
A literature search was performed using Medline (1946 - September 2017) to supplement this 
narrative, state of the art review. In short, two search sets were created and then combined using 
‘and’, using comprehensive search terms for (1) ‘tuberculosis’ and (2) ‘homeless’ or ‘drug users’ or 
‘prisoners’ or ‘vulnerable populations’. This yielded 2,317 articles. Additional articles were identified 
by reviewing references of included studies and review articles, and by consulting experts in the field. 
Original research articles investigating active case finding initiatives or interventions to promote 
adherence among the aforementioned risk groups in low TB-incidence settings (defined as incidence 
<10/100,000) were identified. Studies that focused on contact tracing or specific outbreak 
investigations, or identifying and treating latent TB infection (LTBI) only, were excluded. After 
review of titles, abstracts and full-texts as appropriate, 45 relevant articles were identified (Tables 2 & 
3), with a narrative approach to synthesis.  
 
Box 2: Definitions (adapted from19,82) 
 
Active case finding - systematic identification of people with suspected active TB in a predetermined 
target group. 
 
Adherence - extent to which a patient's history of therapeutic drug-taking coincides with the 
prescribed treatment. 
 
Low TB incidence country – country with annual TB incidence 10 / 100,000 persons. 
 
Passive case finding - a patient-initiated pathway to TB diagnosis that starts with a person presenting 
spontaneously to healthcare services.  
 
Risk group - any group of people in which the prevalence or incidence of TB is significantly higher 
than in the general population. 
 
Screening coverage - proportion of total eligible target population who complete screening.  
 
Screening test - a test that distinguishes people with a high likelihood of having active TB from 
people who are highly unlikely to have active TB. 
 
Screening uptake - proportion of those offered screening who complete it. 
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Figure 1: Flowcharts demonstrating example screening algorithms for mobile X-ray unit service 
screening high-risk populations for active tuberculosis in low-incidence settings using (a) historic 
approach; and (b) new approach incorporating a molecular diagnostic test and automated chest 
radiograph reader. ‘Immediate’ refers to same day referral. Following referral, routine TB 
investigations (including microbiological confirmation) and treatment should occur via local TB 


























Table 1: Table summarising estimated sensitivity and specificity of currently available screening tools for active tuberculosis. Adapted from World Health 
Organization Systematic screening for active tuberculosis: Principles and recommendations19 
 
Screening tool Sensitivity (%) Specificity (%) 
Symptom screen (any symptom) 77 (68–86) 68 (50–85) 
Chest x-ray (any abnormality compatible with TB)  98 (95–100) 75 (72–79) 
Sputum-smear microscopy 61 (31–89) 98 (93–100) 
Xpert MTB/RIF 92 (70–100) 99 (91–100) 
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Table 2: Summary of included studies of active case finding (ACF) among selected risk groups from low tuberculosis (TB) incidence countries. Studies categorised 
according to initial screening step as (a) mobile x-ray unit (MXU) screening; (b) studies using symptom-, TST- or sputum-screening; (c) screening on entry to 
institution; (d) active referral to TB services for screening; (e) one-off prevalence surveys; (f) interventions to encourage screening uptake; and (g) systematic review 
& meta-analysis / modelling. Studies listed by year of publication (reverse chronological order).  
(RFLP = restriction fragment length polymorphism; CXR = chest X-ray; QALY = quality-adjusted life-year; CDC = Centres for Disease Control and Prevention) 
 
Study Year Setting Target population Design, Intervention & Comparator Key Findings 
(a) Mobile x-ray unit screening 




2012 Paris, France  Homeless people  Observational evaluation of 14-year MXU ACF programme in 28 
shelters. No comparator arm. 
179 TB cases / approx. 22,000 screened; reduction in case-
clustering using RFLP from 75% to 30% (p<0.01) 







2012 London, UK  Mixed (homeless, drug 
users, prisoners, asylum-
seekers) 
Observational evaluation of MXU screening programme. 
Compared to passively-detected cases identified through 
routine surveillance.  
Sensitivity of CXR 81.8%; specificity 99.2%. Cases identified 
through screening less likely to be smear-positive than 
passively identified cases (p = 0.022). 33/47,510 CXRs had 
culture-confirmed TB (0.069%) 




2011 London, UK  Mixed (homeless, drug 
users, prisoners, asylum-
seekers) 
Observational cost-effectiveness analysis of ACF using MXU 
intervention. Compared to passively-detected cases identified 
through routine surveillance. 
 
Case-detection intervention was cost-effective (£18,000-
£26,000/QALY gained) 







Homeless people and drug 
users  
Observational evaluation of voluntary MXU ACF. No comparator 
arm. 
28 TB cases identified (prevalence 327/100,000 CXRs), 12 
smear-positive; reduction in clustered cases over time using 
RFLP (80% to 45%) 







2007 London, UK  Mixed (homeless, drug 
users, prisoners, asylum-
seekers) 
Observational evaluation of voluntary MXU screening, 
Compared to passively-detected cases identified through 
routine surveillance. 
 
222/20,357 individuals screened referred; 154 (69%) seen 
by TB services; 43 commenced on TB treatment. Passively-
detected cases had almost 3 x delay to diagnosis and risk of 
smear-positivity than ACF cases. 




1999 London, UK  Homeless people  Observational evaluation of screening with symptom 
questionnaire, TST and CXR on-site. Lunch voucher to 
encourage uptake. No comparator arm. 
10/2,000 (0.5%) had active TB; symptom questionnaire 'not 
useful'; 80% treatment completion 






Homeless people  Observational evaluation of voluntary MXU ACF in 5 hostels; 
referral to TB service if TB suspected. No comparator arm. 
506/3555 screened (14.2%) had abnormal CXR. Only 2 
cases of active TB (0.05%). Approx. 50% of those with 
abnormal chest x-ray lost to follow-up. 








1992 London, UK  Homeless people  Observational evaluation of voluntary MXU screening. No 
comparator arm. 
547 screened; screening uptake 44%; 42% attendance at 
follow-up for abnormal CXRs; 0 new cases of TB identified 





1986 Edinburgh, UK Homeless Observational evaluation of voluntary MXU screening. 
Compared to passively-detected cases identified through 
routine surveillance. 
 
42/4687 (0.9%) of CXRs had TB (65% of all TB cases in 
hostel-dwellers). Fewer ACF cases were sputum smear 




1985 Glasgow, UK Homeless Observational evaluation of voluntary MXU screening with food 
voucher incentive. No comparator arm. 
 
Uptake 47%; 133/9,132 screened had TB (1.5%) 
(b) Studies using symptom-, TST- or sputum-screening 







Homeless people  Observational evaluation of screening with questionnaire 
(symptoms, epidemiological risk). Chest x-ray screening 
performed if score >10. No comparator arm. 
 
Uptake 87.3%; 30/726 (4.1%) positive questionnaire; 0/24 
referred for testing had active TB 
Jensen et al.27  2015 Copenhagen, 
Denmark 
Mixed (homeless persons; 
persons with alcohol and/or 
substance abuse; and 
other socially marginalised 
persons)  
 
Observational evaluation of screening using sputum microscopy 
& culture at 11 locations, on 7 occasions. No comparator arm. 
36 / 1075 had TB. 24 cases identified at first screening of 
each participant (prevalence 2233/100 000). 35/36 (97.2%) 
TB cases culture-positive; 7/36 (19.4%) smear-positive; 
28/36 (77.8%) had chest X-ray suggestive of TB. 30/36 
(83.3%) had a successful outcome.  
 







2009 New York 
City, USA 
As McAdam et al., 2009 Observational evaluation of screening with symptom 
questionnaire & TST. Sputum smear & culture, and CXR if TST-
positive (or previous TST or active TB). No comparator arm. 
Coverage 3-13.9% of homeless population. 63/28,835 active 
TB (0.24%). Incidence fell from 1,502/100,000 (1992) to 
171/100,000 (2004) 









2006 Texas, USA Homeless people and 
prisoners (parallel 
interventions compared) 
Observational evaluation of screening with symptom 
questionnaire & TST. Further investigations if TST positive. 
Selection for homeless screening unclear. Cases treated under 
DOT. Incentives for treatment provided for homeless (dietary 
supplements or fast-food coupons). No comparator arm. 
 
Homeless - 10 /822 active TB (1.2%); prisoners 7/22,920 
active TB (0.03). Estimated that LTBI treatment of homeless 
persons and jail inmates will avert 11.9 and 7.9 TB cases at 
a cost of $14,350 and $34,761 per TB case, respectively 







2002 Denver, USA Homeless people and drug 
users  
Observational evaluation of screening with symptom screen & 
TST at 4 shelters and 6 drug recovery programmes. If either 
positive, referral to TB service. Screening required to stay at 
shelter / drug programme. No comparator arm. 
 
Estimated TB incidence among all homeless decreased from 
510 to 121 cases / 100,000 / year during intervention years. 
Recent transmission (DNA fingerprinting definition) 
decreased from 49% to 14% (p=0.03).  
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Griffin & Hoff30 
 
 
1999 Kansas, USA Homeless people  Observational evaluation of screening with TST screening; CXR 
in TST positive cases. No comparator arm. 
0 cases of active TB; 89/856 TST positive 








Homeless people  Observational evaluation of screening with sputum culture, 
symptom screen (and TST in round 1/4) for overnight clients. No 
comparator arm. 
4/127 screened (3.1%) had TB. 3/4 clustered using RFLP. 
Costs estimated to be $1311/case identified. Only 1/4 cases 
reported productive cough on symptoms screen 







1990 New York 
City, USA 
Homeless people attending 
shelter clinic (for work 
programme clearance or 
for evaluation of any 
medical problem) 
Observational evaluation of screening with symptom 
questionnaire & TST. Sputum smear & culture, and CXR if TST-
positive (or previous TST or active TB). No comparator arm. 
100/1,853 (6%) had active TB. Treatment completion 36% 
(c) Screening on entry to institution 







Prisoners Cross-sectional evaluation of adherence to CDC TB control 
policy. Symptom screen and TST on arrival (as per CDC 
guidance); if either positive, referral for CXR and clinical 
evaluation. No comparator arm. 
 
28/97 of intake health interviews conducted correctly. Delays 
noted in diagnostic testing of 51 detainees isolated for 
suspected TB.  






2001 San Diego, 
USA 
Prisoners Observational evaluation of screening with symptom review, 
TST, and CXR for all new entrants. Compared to previous policy 
of only symptoms review and TST. 
8/1,830 screened with universal CXR had TB (no change in 
incidence from previous practice). CXR screening of all 
inmates reduced exposure time to active TB cases by 75% 






Homeless people  Observational evaluation of screening with TST, CXR and 
sputum (if CXR suggestive) in people entering shelters. No 
comparator arm. 
 
5/447 (1.1%) had active TB; 335 (75%) had LTBI 









Prisoners  Observational evaluation of screening with symptom screen and 
TST on arrival (as per CDC guidance); if either positive, referral 
for CXR and clinical evaluation. No comparator arm. 
 
In 1994, 25 active TB cases booked into the jail (prevalence 
78.5/100,000); only 3/25 were new diagnoses. In 1998, 21 
active TB cases booked in (prevalence 72.1/100 000); only 
7/21 new diagnoses. 





1998 Georgia, USA Prisoners Observational evaluation of screening with symptom screen and 
TST on arrival (as per CDC guidance); if either positive, referral 
for CXR and clinical evaluation. No comparator arm. 
 
142 TB cases identified; 74% detected through screening. 
38% lost-to-follow-up 






1996 Chicago, USA Prisoners  Observational evaluation of screening with miniature CXR on 
arrival. Compared to previous approach using TST screening.  
86/126,608 (0.07%) screened had TB; 67 diagnosed by X-
ray and 19 by diagnostic work-up. Mean time from entry to 
isolation reduced from 17.6 days with TST screening to 2.3 
days with CXR screening. 









Prisoners Observational evaluation of screening with TST. CXR if TST-
positive or HIV-positive. Sputum microscopy/culture if CXR 
abnormal. No comparator arm. 
 
TB diagnosed in 12/944 (1.26%); only 4/12 cases were new 
diagnoses via screening 






Prisoners Observational evaluation of screening with TST. CXR if TST or 
HIV-positive. Sputum microscopy/culture if CXR abnormal. No 
comparator arm. 
 
19/702 (2.7%) who completed screening had TB 




1993 New York 
City, USA 
Persons admitted to an 
opiate detoxification unit in 
an urban jail 
Observational evaluation of screening with TST & CXR 
screening. No comparator arm. 
73/1,314 had CXR changes consistent with active TB 
(d) Active referral to TB services for screening 
Jimenez-







Drug users, 'economically 
disadvantaged' & recent 
migrants from 
hyperendemic countries 
Observational evaluation of referral to TB service for clinical 
evaluation and chest X-ray screening (from various referral 
sources). No comparator arm. 
30/5,982 screened had TB (0.5%). Prevalence 1.77% in 
recent migrants; 0.30% in economically disadvantaged; 
0.62% in drug users 






Drug users and homeless 
persons 
Observational evaluation of referral for departmental CXR 
screening by community health workers. No comparator arm. 
 
Screening coverage 18-26%; 39/3477 screened had TB 
(1.1%) 
(e) One-off prevalence surveys 








Homeless people  Observational evaluation of comprehensive, multidisciplinary 
screening of participants including symptom screen, sputum 
microscopy & culture, chest radiograph. No comparator arm. 
 
2/221 (1%) had TB 





1995 London, UK  Homeless people  Observational evaluation of symptom & CXR screening for two 
years. In year one, CXR only if symptomatic. In year two, chest 
x-ray universal. No comparator arm. 
 
595/3600 (16.5%) accepted screening; 30/595 (5%) had 
changes suggestive of active tuberculosis. 9/595 (1.5%) had 
confirmed TB; 13 did not attend follow-up 




1986 Boston, USA Homeless people  Observational evaluation of one-off active case finding with 
TST, CXR, sputum culture over 4-night period. No comparator 
arm. 
3/586 (0.5%) had confirmed TB 
(f) Interventions to encourage screening uptake 




2015 London, UK  Homeless people  Cluster RCT (46 hostels; 2,342 participants) of volunteer peer 
educators to encourage MXU screening uptake. Compared to 
standard care.  
 
No difference in uptake between peer educator (median 
40%) and control (median 45%) hostels 




2003 New York 
City, USA 
Drug users attending 
needle-exchange 
programme 
Observational evaluation of monetary incentive to attend 
external chest x-ray screening (if TST positive). Compared to 
historical approach with no monetary incentive.  
 
Adherence to CXR referral within 7 days 79% with monetary 
incentive vs. 14% without (p<.0001). Median time to CXR 
shorter among those given incentive (2 vs. 11 days; p < 
.0001) 














Homeless people  RCT of monetary incentives vs peer health advisor vs standard 
care to encourage TST positive people to attend TB clinic for 
further screening. 
69 (84%) with monetary incentive completed first follow-up 
appointment, vs. 62 (75%) with peer health adviser vs 42 
(53%) with usual care. 3/173 (1.7%) screened had active TB 
(g) Systematic review & meta-analysis / modelling 






2014 N/A Homeless people  Systematic review and meta-analysis of CXR screening Pooled prevalence of active TB in 16 study cohorts 
931/100,000 population screened. 6/7 longitudinal screening 
programs reported reduction in regional TB incidence after 
implementation 






Homeless people and drug 
users  
Modelling study using truncated models to estimate coverage of 
MXU ACF 
Screening programme reached approx. 2/3 of estimated 
target population at least annually 





2001 USA  Homeless people  Modelling study in US homeless populations using computer-
based simulation model to examine impact of TB-control 
strategies on projected TB cases and deaths. 
 
10% increase in access to treatment among homeless 
persons with active TB produced largest declines in 





2001 USA  Prisoners  Cost-effectiveness analysis using primary data from literature 
review of miniature CXR screening. 
Cost of screening with miniature chest radiography 
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Table 3: Summary of included studies of interventions to improve adherence and treatment completion among selected risk groups from low tuberculosis (TB) 
incidence countries. Studies categorised as (a) Studies using enhanced case management; (b) studies using DOT; (c) studies using incentives. Studies listed by year 
of publication (reverse chronological order). 
(ACF = active case finding; DOT = directly observed therapy). 
 
Study Year Setting Target population Design, Intervention & Comparator 
 
Key findings 
(a) Studies using enhanced case management   
Goetsch et al.48 2012 Frankfurt, Germany Drug users and homeless 
persons 
Observational evaluation of enhanced case management, 
hospital admission for initiation of treatment. No comparator 
arm. 
 
Treatment completion 76% 
Jit et al.38 2011 London, UK  Mixed (including homeless 
people, prisoners, drug 
users, asylum seekers) 
Observational evaluation of enhanced case management with 
treatment support by peers. Compared to passively detected 
cases (from routine surveillance). 
  
Case-management highly cost-effective (£4100-
£6800/QALY gained). Treatment completion 61.2% (vs. 
51.7%) in case management cohort.  
 











Homeless people and drug 
users  
Observational evaluation of DOT, and a range of other 
enhanced case management approaches including  
priority shelter accommodation, voluntary admission to TB 
hospitals, assistance applying for temporary residence permits. 
Detention as a last resort (14 patients). Incentives such as public 
transport tickets also provided. No comparator arm.  
 
Treatment completion 89.2% 
 




1999 San Diego, USA Homeless persons Observational evaluation of DOT and supervised 
accommodation provided. No comparator arm.  
 
Treatment completion achieved in 18/20 cases. Cost 
savings for infectious patients estimated as $27,034 per 
patient. 
Diez et al.71 1996 Barcelona, Spain  Homeless people  Observational evaluation of DOT, primary health care & 
accommodation. Compared with historical trends.  
Decrease in local TB incidence among homeless (from 32.4 
to 19.8 per 100,000 from 1987-1992; p = 0.03). 19.6% of 
patients failed to complete treatment, and decrease in 
mean period of hospitalization from 27.1 to 15.7 days from 
1986-1992 
 
(b) Studies using DOT    
Ricks et al.75 2015 Chicago, USA Drug users RCT. Substance users randomized to DOT administered by 
either 1) public health personnel (standard arm) or 2) previous 
substance-using or HIV/AIDS outreach workers (enhanced arm) 
 
Standard arm had a significantly higher risk of non-
completion of treatment (39% vs. 15%) 
Kim et al.73 2007 Chicago, USA Prisoners  Observational comparison of those who received DOT vs those DOT associated with higher treatment completion (59% vs 
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who did not. 29.1%); higher if DOT in community (70.8% field DOT vs 
43.5% clinic DOT) 
 
Juan et al.74 2006 Valencia, Spain Mixed population at risk 
for non-adherence (HIV, 
alcoholism, drug use, 
immigrant or homeless 
and/or previous failure to 
complete) 
 
Observational evaluation of pharmacy-delivered DOT compared 
to historic self-administration cohort 
Treatment completion 75.2% in DOT group, vs. 26.7% self-
administration group (P < 0.001). DOT increased cost of 
treatment by 400 Euros. 
(c) Studies using incentives    
Bock et al.76 2001 Georgia, USA Mixed, non-adherent TB 




Observational evaluation of $5 grocery voucher for each kept 
DOT attendance. Compared to historical cohort.  
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